This study aims to provide long-term follow-up for participants who previously received a gene therapy called HMI-102. To take part, participants must have been given HMI-102 in an earlier study and be able to comply with all follow-up procedures. It is a non-phase follow-up study and enrolls by invitation.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * Subject was previously administered HMI 102. * Subject is able to understand the purpose and risks of the study and is willing to provide informed consent. * Subject is able to comply with all study procedures and long-term follow-up. Exclusion Criteria: * Participation in the study is not in the subject's best interest, in the opinion of the Investigator.